Effect of geniposide on metabolic syndrome rats and its influence on adipocytokines
QIAN Xiufang1, XU Changqing1, ZHU Zhe1, LI Juan2
1. Department of Pharmacy, Beijing Municipal Corps Hospital of Chinese People's Armed Police Force, Beijing 100027, China; 2. Department of Urology, the Third Medical Centre of PLA General Hospital, Beijing 100039, China
Abstract：Objective To explore the effect of geniposide on high fat/high fructose diet-induced metabolic syndrome (HFFD-MS) and its influence on the adipocytokines. Methods HFFD-MS models of rats were induced by a 16-week high-fat/high-fructose diet, and were randomly divided into model group, geniposide dose groups (30, 60 and 120 mg/kg, respectively), and positive control (metformin 50 mg/kg) group, while the other rats fed with ordinary diet and pure water in the same period were divided into normal group with 10 rats in each group. After 8 weeks of intragastric administration, the fat-body ratio and insulin resistance (HOMA-IR) were calculated, fasting blood glucose (FBG), total cholesterol (TC), triglyceride (TG), free fatty acid (FFA), and insulin (INS) levels in serum were detected, and the pathologic changes were observed in perirenal adipocytes. The serum levels of adipocytokine leptin (LP), visfatin (VIS), adiponectin (APN), resistin (RES), tumor necrosis factor α (TNF-α) and interleukin 6 (IL-6) were detected by radioimmunoassay. Results The perirenal adipocytes in geniposide dose groups were smaller and more tightly arranged than those in the model group. Compared with the model group, geniposide administration significantly reduced the body and visceral fat weights, and fat-body ratio in HFFD-MS rats (P<0.05), significantly down-regulated FBG, HOMA-IR and serum TC, TG, FFA and INS levels (P<0.01), significantly reduced serum LP, RES, TNF-α and IL-6 levels (P<0.05 or P<0.01), and the high-dose of geniposide evidently up-regulated the expression of APN (P<0.01). Geniposide administration had no significant effect on VIS. Conclusions Geniposide can obviously improve the pathological process of HFFD-MS by regulating the abnormal secretion of adipokines, reducing the accumulation of visceral fat and correcting the disorder of glucose-lipid metabolism.
Zhou Y X, Zhang R Q, Rahman K, et al. Diverse pharmacological activities and potential medicinal benefits of geniposide[J]. Evid Based Complement Alternat Med, 2019,2019:4925682.
[2]
刘金鑫. 京尼平苷调控小鼠糖脂代谢的机理研究[D]. 无锡: 江南大学,2021.
[3]
Gao S, Feng Q. The beneficial effects of geniposide on glucose and lipid metabolism: a review[J]. Drug Des Devel Ther, 2022,16:3365-3383.
[4]
Moreno-Fernández S, Garcés-Rimón M, Vera G, et al. High fat/high glucose diet induces metabolic syndrome in an experimental rat model[J]. Nutrients, 2018, 10(10): 1502.
[5]
Saeed S, Waje A U, Nilsson P M. The association of the metabolic syndrome with target organ damage: focus on the heart, brain, and central arteries[J]. Expert Rev Cardiovasc Ther, 2020,18(9):601-614.
Ma Z G, Kong C Y, Song P, et al. Geniposide protects against obesity-related cardiac injury through AMPKα- and Sirt1-dependent mechanisms[J]. Oxid Med Cell Longev, 2018,2018:6053727.
Ross R, Després J P. Abdominal obesity, insulin resistance, and the metabolic syndrome: contribution of physical activity/exercise[J]. Obesity (Silver Spring), 2009,17 (Suppl 3):S1-S2.
Jiang B, Chen Y, Zhou K, et al. Comparison of abdominal obesity and fattyliver and their association with insulin resistance and metabolic syndrome in Chinese adults[J]. Obesity (Silver Spring), 2019,27(5):707-715.
Lei R, Chen S, Li W. Advances in the study of the correlation between insulin resistance and infertility[J]. Front Endocrinol (Lausanne), 2024,15:1288326.
[14]
Xu S, Ren R, Li W, et al. The association between obesity indicators and metabolic risk factors in type-2 diabetic patients[J]. Heliyon, 2023,9(9):e20013.
[15]
Li G, Robles S, Lu Z, et al. Upregulation of free fatty acid receptors in periodontal tissues of patients with metabolic syndrome and periodontitis[J]. J Periodontal Res, 2019,54(4): 356-363.
[16]
Aisike G, Kuerbanjiang M, Muheyati D, et al. Correlation analysis of obesity phenotypes with leptin and adiponectin[J]. Sci Rep, 2023,13(1):17718.
[17]
Ugur K, Erman F, Turkoglu S, et al. Asprosin, visfatin and subfatin as new biomarkers of obesity and metabolic syndrome[J]. Eur Rev Med Pharmacol Sci, 2022,26(6):2124-2133.
[18]
Bajpai A. HOMA-AD and metabolic syndrome-the homecoming of adiponectin in pediatric obesity[J]. Indian J Pediatr, 2021,88(4):322-323.
[19]
Primo D, Izaola O, Luis D. Resistin/uric acid index as a marker of metabolic syndrome in females with obesity[J]. Int J Obes (Lond), 2023,47(5):393-398.
[20]
Mohammadi M, Gozashti M H, Aghadavood M, et al. Clinical significance of serum IL-6 and TNF-α levels in patients with metabolic syndrome[J]. Rep Biochem Mol Biol, 2017,6(1):74-79.
2024, Vol. 35 
